文献速递肾移植血液净化与透析

肾功能衰竭移植肾的管理:诸多问题尚待解决

Managing Patients with Failing Kidney Allograft: Many Questions Remain.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-03-10

本文综述了移植肾衰竭患者的管理策略,涵盖免疫抑制撤减时机、向二次移植或透析过渡的决策,并指出当前证据质量较低、实践差异大,且此类患者较未移植者存在超额发病率和死亡率。

要点

  • 移植肾衰竭管理证据质量低,实践模式差异大且欠优化
  • 免疫抑制撤减时机与方式、向二次移植或透析过渡是核心决策
  • 需权衡致敏与感染等竞争风险,移植肾衰竭患者发病率和死亡率高于未移植者

核心结论

  • 移植肾衰竭的管理目前由质量较差的数据指导,实践模式差异大且次优。
  • 移植肾衰竭患者较未移植者存在超额发病率和死亡率。

研究设计与样本

  • 综述,总结从移植向透析过渡期间的管理策略。

主要发现

  • 移植肾衰竭常伴随复杂管理决策,如免疫抑制撤减时机与方式及向二次移植或透析过渡。
  • 决策需权衡致敏和感染等竞争风险。
  • 当前证据匮乏,存在关键知识缺口。

临床怎么用

  • 临床需在缺乏高质量证据下个体化决策免疫抑制撤减及肾脏替代治疗过渡。

局限性

  • 指导管理的数据质量相对较差。
  • 知识存在关键缺口,需进一步研究以优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients who receive a kidney transplant commonly experience failure of their allograft. Transplant failure often comes with complex management decisions, such as when and how to wean immunosuppression and start the transition to a second transplant or to dialysis. These decisions are made in the context of important concerns about competing risks, including sensitization and infection. Unfortunately, the management of the failed allograft is, at present, guided by relatively poor-quality data and, as a result, practice patterns are variable and suboptimal given that patients with failed allografts experience excess morbidity and mortality compared with their transplant-naive counterparts. In this review, we summarize the management strategies through the often-precarious transition from transplant to dialysis, highlighting the paucity of data and the critical gaps in our knowledge that are necessary to inform the optimal care of the patient with a failing kidney transplant.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Davis S, Mohan S. Managing Patients with Failing Kidney Allograft: Many Questions Remain. Clin J Am Soc Nephrol. 2021. PMID: 33692118. doi:10.2215/CJN.14620920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。